Research programme: enzyme therapeutics - Codexis

Drug Profile

Research programme: enzyme therapeutics - Codexis

Alternative Names: CDX-6114; Phenylketonuria therapeutic enzyme - Codexis

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Codexis
  • Class Enzymes
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Phenylketonuria

Most Recent Events

  • 09 Aug 2017 Codexis plans a clinical trial for CDX 6114 in Phenylketonuria in early 2018
  • 09 Mar 2017 Codexis announces intention to submit IND for Phenylketonuria with the US FDA in 2018
  • 30 Sep 2016 Enzymes licensed to undisclosed Biopharmaceutical partner before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top